[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 10
1. Navarro WH, Kaplan LD: AIDS-related lymphoproliferative disease. Blood; 2006 Jan 1;107(1):13-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoproliferative disease.
  • Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.
  • Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.
  • Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Transplantation. Humans. Lymphoproliferative Disorders / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099881.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


2. Flaitz CM, Nichols CM, Walling DM, Hicks MJ: Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncol; 2002 Jan;38(1):96-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations.
  • Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity.
  • Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded.
  • Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma.
  • Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominantly involves the oral cavity, may mimic KS and has a poor prognosis.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Mouth Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Fatal Outcome. HIV Infections / drug therapy. Humans. Male. Middle Aged. Sarcoma, Kaposi / diagnosis


3. Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM: Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma; 2002 Feb;43(2):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.
  • Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) producing sheets of cells with an organoid distribution.
  • These studies were supportive of a diagnosis of a plasmablastic lymphoma.
  • Plasmablastic lymphoma is now reported in some studies to account for 2.6% of all HIV-related NHL.
  • The regression of disease after resumption of HAART therapy alone in this patient suggests that HAART has an important role in the treatment of lymphoma in the HIV infected patient.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. HIV Infections / complications. HIV Infections / drug therapy. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / virology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Remission Induction


Advertisement
4. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / complications. Fatal Outcome. Humans. Male. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Transplantation, Autologous. Vincristine / administration & dosage


5. Spina M, Gloghini A, Tirelli U, Carbone A: Therapeutic options for HIV-associated lymphomas. Expert Opin Pharmacother; 2010 Oct;11(15):2471-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMPORTANCE OF THE FIELD: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population.
  • The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients.
  • [MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / trends. Boronic Acids / therapeutic use. Bortezomib. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / drug therapy. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Pyrazines / therapeutic use. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726820.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 0 / ofatumumab; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


6. Corti M, de Dios Soler M, Bare P, Villafañe MF, De Tezanos Pinto M, Perez Bianco R, Narbaitz M: [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8]. Medicina (B Aires); 2010;70(2):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8].
  • [Transliterated title] Linfomas asociados con la infección por el virus de la inmunodeficiencia humana: subtipos histológicos y asociación con los virus de Epstein Barr y Herpes-8.
  • Non-Hodgkin lymphomas (NHL) of the B-cell type are the second most common neoplasm among patients with human immunodeficiency virus (HIV) infection and AIDS.
  • Here, we evaluated 48 cases of AIDS-related lymphomas (ARL) diagnosed at the Histopathological Division of the Instituto de Investigaciones Hematológicas of the National Academy of Medicine.
  • Additionally, biotinilated oligonucleotides were used to determine the presence of DNA of the Human Herpes virus type-8 (HHV-8) in 14/14 biopsy smears corresponding to plasmablastic lymphomas (PL).
  • Virological findings showed the strong association between EBV and AIDS-related NHL.
  • According to the histopathological subtype, the EBV genome was detected in 16/21 (76%) diffuse large B cell lymphomas, 1/3 Burkitt lymphoma and 3/4 (75%) of primary central nervous system lymphomas.
  • Hodgkin lymphoma were more frequent in males 18/20 (90%), with an aggressive clinical course and a significant predominance of the subtypes associated with worse prognosis (90% of cases).
  • We consider that all cases of AIDS related lymphomas should be assessed for the presence of EBV because its presence may play a role in the prognosis.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447898.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


7. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN: Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist; 2010;15(3):293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals.
  • Further research is needed to improve responses using novel therapeutic agents and strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(3):194 [10942339.001]
  • [Cites] J Hematol Oncol. 2009;2:47 [19909553.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1582-4 [12824797.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):761-5 [17094093.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Eur J Haematol. 2009 Jun;82(6):490-2 [19220417.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]
  • [Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • (PMID = 20167839.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC3227958
  •  go-up   go-down


8. Sarek G, Ojala PM: p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle; 2007 Sep 15;6(18):2205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV infection is the causative agent in three different tumor types: Kaposi's sarcoma, a plasmablastic variant of multicentric Castelman's disease and an AIDS-related form of B cell lymphoproliferative disorder called primary effusion lymphoma (PEL).
  • PEL manifests as an effusion malignancy in Kaposi's sarcoma patients with advanced AIDS, but also occurs in HIV-negative individuals.
  • [MeSH-major] Herpesvirus 8, Human / pathogenicity. Lymphoma, AIDS-Related / therapy. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / therapy. Sarcoma, Kaposi / virology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Animals. Humans. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890905.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 66
  •  go-up   go-down


9. Yotsumoto M, Ichikawa N, Ueno M, Higuchi Y, Asano N, Kobayashi H: CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. Intern Med; 2009;48(7):559-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient.
  • Many plasmablastic atypical lymphocytes were observed in the peripheral blood.
  • He was diagnosed with diffuse large B cell lymphoma (DLBCL) by a biopsy of the inguinal lymph node.
  • He showed a transient response to multi-agent chemotherapy, and during the course of salvage chemotherapy, he died of urinary infection.
  • This case has unique clinical features compared with previously reported DLBCLs with plasmablastic differentiation.
  • [MeSH-major] Antigens, Neoplasm / analysis. Genes, myc. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Syndecan-1 / analysis. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cytomegalovirus Retinitis / complications. Cytomegalovirus Retinitis / drug therapy. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / diagnosis. Fatal Outcome. Ganciclovir / therapeutic use. Humans. Lymph Nodes / pathology. Male. Middle Aged. Salvage Therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Urinary Tract Infections / complications. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336959.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; P9G3CKZ4P5 / Ganciclovir; VAD I protocol
  •  go-up   go-down


10. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood; 2009 Feb 5;113(6):1213-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system).
  • Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease.
  • These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells.
  • EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression.
  • (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
  • [MeSH-major] Gammaherpesvirinae / pathogenicity. HIV-1 / pathogenicity. Herpesviridae Infections / virology. Lymphoma, AIDS-Related / virology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Humans. Tumor Virus Infections / pathology. Tumor Virus Infections / therapy. Tumor Virus Infections / virology






Advertisement